

Special Issue

Radiopharmaceuticals and Sarcopenia

Message from the Guest Editors

Sarcopenia is defined as a loss of skeletal muscle mass and function related to aging, drugs, or malignancy. It is a systemic disease that is characterized by degenerative change, inflammatory process, mitochondrial dysfunction, etc. Since sarcopenia is associated with functional impairment, disability, falls, fractures, and other consequences that reduce the quality of life and increased mortality, it presents an issue of growing concern particularly in the developing world and aging world. This Special Issue invites research and review articles on the use of radiopharmaceuticals as a tool to study the mechanisms of sarcopenia. The mechanisms covering aging, inflammation, metabolism, nutrition, protein synthesis, drugs, and malignancy are some of the research areas that this Special Issue aims to include. The use of radiopharmaceuticals to study the anatomy, physiology or pathology of adipose tissue, skeletal muscle, and body composition is also welcome.

Guest Editors

Dr. Kuen-Chang Hsieh

Big Data Center, National Chung Hsing University, Taichung 40227, Taiwan

Dr. Li-Wen Lee

School of Medicine, Chang Gung University, Taoyuan, Taiwan

Dr. Hsueh-Kuan Lu

General Education Center, National Taiwan University of Sport, Taichung, Taiwan

Deadline for manuscript submissions

closed (25 January 2024)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/166801

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)